Skip to main content

Table 2 a. Responses of tumor in MVI and main tumor to one-shot CDDP chemotherapy plus RT, as assessed by mRECIST. b Responses of tumor in MVI and main tumor to one-shot CDDP chemotherapy plus RT, as assessed by RECIST 1.1

From: Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study

  HAI + RT (n = 32)  
  First-time response (median, 1.4 month) Best response
  Whole tumor Main tumor MVI Whole tumor Main tumor MVI
(a)       
CR 0 0 0 0 0 0
PR 16 (5) 16 (5) 59 (19) 16 (5) 16 (5) 59 (19)
SD 25 (8) 25 (8) 28 (12) 25 (8) 25 (8) 28 (12)
PD 59 (19) 59 (19) 3 (1) 59 (19) 59 (19) 3 (1)
ORR 16 (5) 16 (5) 59 (19) 16 (5) 16 (5) 59 (19)
DCR 41 (13) 41 (13) 97 (31) 41 (13) 41 (13) 97 (31)
(b)       
CR 0 0 0 0 0 0
PR 9 (3) 9 (3) 25 (8) 16 (5) 16 (5) 56 (18)
SD 32 (10) 32 (10) 72 (23) 25 (8) 25 (8) 43 (13)
PD 59 (19) 59 (19) 3 (1) 59 (19) 59 (19) 3 (1)
ORR 9 (3) 9 (3) 25 (8) 16 (5) 16 (5) 56 (18)
DCR 41 (13) 41 (13) 97 (31) 41 (13) 41 (13) 97 (31)
  1. The best and first-time response of tumor in MVI and main tumor to one shot CDDP chemotherapy via HAI plus RT, as assessed by mRECIST and RECIST 1.1. The median period of the first-time response was assessed was 1.4 months from HAI. Data are presented as percentages (numbers). MVI macrovascular invasion; CDDP cisplatin; RT radiation therapy; CR complete response; PR partial response; SD stable disease; PD progressive disease; ORR overall response rate; DCR disease control rate; mRECIST modified Response Evaluation Criteria in Solid Tumors